Vitiligo Surgical Treatment Advances
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium, interviewed Dr. Iltefat Hamzavi, a dermatologist with Henry Ford Health and associate professor of dermatology at Wayne State University School of Medicine. Learn from Dr. Hamzavi the key pillars of vitiligo treatment, and why there’s room to improve available options for melanocyte recruitment and repair. Dr. Hamza …
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium, interviewed Dr. Iltefat Hamzavi, a dermatologist with Henry Ford Health and associate professor of dermatology at Wayne State University School of Medicine. Learn from Dr. Hamzavi the key pillars of vitiligo treatment, and why there’s room to improve available options for melanocyte recruitment and repair. Dr. Hamza … 
The Journal of Drugs in Dermatology welcomes 2024 with a strong line up of original articles, case reports, brief communications, and letters to the editor. Straight from the Editor's desk, we share this month's issue highlights!
ORIGINAL ARTICLES
Current Landscape of Hyaluronic Acid Filler Use in the United States shares the results of a comprehensive search of all the FDA approved dermal fill … 
Which of the following histopathologic features is most likely to be encountered in this patient with pruritic hand lesions?
A. Eosinophilia
B. Floor-pattern salt-split skin
C. Leukocytoclasia
D. Parakeratosis
E. Spongiosis
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
… 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Diane S. Berson, associate professor of dermatology at Weill Cornell Medical College. Watch as Dr. Berson shares the cosmeceutical ingredients that dermatology clinicians can use synergistically to address photodamage and hyperpigmentation. Learn what ingredients are newly available and how cosmeceutica … 
Alitretinoin (9-cis-retinoic acid) is a naturally occurring endogenous retinoid that in gel form is FDA approved for AIDs-related localized cutaneous Kaposi’s sarcoma (KS)1. As compared to other topical retinoids, alitretinoin is unique in that it binds to all known intracellular retinoid receptors (RARs and RXRs), allowing it to exert anti-proliferative and apoptotic effects, particularly usefu …